CIK 0000907654
- Non-accelerated filer
- Smaller reporting company
Oruka Therapeutics, Inc.
Sign in to watch- Ticker
- ORKA
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- Operating
- EIN
- 363855489
- Phone
- +1 650-606-7910
- Business address
- 855 OAK GROVE AVE., SUITE 100, MENLO PARK, CA, 94025
- Former names
- ARCA biopharma, Inc., NUVELO INC, HYSEQ INC
- 4 Other acquisition C.E.O. acquired 7,247 shares (code I)
- 4 Other acquisition Sr. VP CFO and General Counsel acquired 5,263 shares (code I)
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Other acquisition Sr. VP Research & Development acquired 740 shares (code I)
- 4 Other acquisition C.E.O. acquired 292 shares (code I)
- 4 Other acquisition Sr. VP Finance and CFO acquired 229 shares (code I)
- 4 Other acquisition Sr VP & General Counsel acquired 350 shares (code I)
- 4 Open-market sale Director sold 12,500 shares at $18.17 ($227,136)
- 4 Exercise or conversion Director acquired 65,833 shares (option exercise)
- 4 Open-market sale Chief Acct.Officer sold 14,000 shares at $20.70 ($289,800)
- 4 Open-market sale Chief Acct.Officer sold 6,831 shares at $20.65 ($141,060)
- 4 Open-market sale Chief Acct.Officer sold 40,000 shares at an average $19.94 ($797,502)
- 4 Open-market sale Chief Acct.Officer sold 15,000 shares at $19.50 ($292,500)
- 4 Open-market sale Director sold 12,500 shares at $16.00 ($200,000)
- 4/A Open-market sale Director sold 12,500 shares at an average $15.59 ($194,818)
Page 18 of 23 · 459 filings